Reference tool

Peptide stacking & timing

Most stacking questions are really one of four questions: are these two hitting the same receptor, are they pulling glucose in the same direction, are their acute effects landing in the same window, and can they physically share a vial. This page scores all 55 compounds in the encyclopedia against those four axes and returns a verdict for every one of the 1,485 possible pairs.

A worked example: why one common morning combination produces an uncomfortable rush

CJC-1295 / Ipamorelin, B12, NAD+ and MOTS-c, co-administered in a fasted state.

This grouping comes up constantly, and the reaction it produces is consistently described the same way: a large, not-entirely-pleasant rush within the first fifteen minutes. The useful thing about it is that no pair in it is chemically incompatible. Nothing is interacting. Three of the four simply produce the same acute vasoactive effect, and all three peak inside the same 5-to-30-minute window. The result is not four mild effects — it is one effect, three times over.

NAD+ dominates the picture. In the published tolerability work, essentially every intravenous recipient reported cramping, nausea, raised heart rate and chest pressure, all resolving once the infusion ended. The leading explanation is that supraphysiologic extracellular NAD+ acts as a proinflammatory danger signal through purinergic signalling — not a simple flush. It is strongly rate- and dose-dependent: participants in that study slowed their own infusions to around 97 minutes. Worth stating plainly that this data is all intravenous; subcutaneous NAD+ tolerability is essentially undocumented.
The secretagogue flush lands on top of it. The common explanation — that the growth-hormone pulse causes the vasodilation — does not survive the timeline. Subcutaneous GH does not peak until 20 to 60 minutes, while the flush appears at 5 to 15. It is a direct receptor-level vascular effect of the GHRH analog.
MOTS-c may contribute, but the evidence is thin. Its AMPK activation and glucose-lowering come from mouse and cell-culture work; there are no human dosing trials and no documented hypoglycemia in people. What is well established is the opposite direction — GH secretagogues themselves impair glucose tolerance.
B12 is likely a bystander. Reports that methylcobalamin produces a wired feeling are forum-level, with no controlled data and no plausible mechanism for a water-soluble vitamin.

The principle this illustrates generalises across the catalog: acute vasoactive load is additive and it is what “uncomfortable rush” usually means. The checker below scores it explicitly, and the timing view distributes it rather than removing anything.

Ten rules that cover most of the catalog

One GHRH plus one GHRP — never two of either. Sermorelin, CJC-1295 and tesamorelin are all GHRH analogs; ipamorelin, GHRP-6 and hexarelin all act at the same ghrelin receptor. Combining across the two families is genuinely superadditive and has been replicated in several cohorts since Bowers demonstrated it in 1990. Combining within one family adds side effects and nothing else. The CJC-1295 / Ipamorelin blend is already both — a complete pairing, not a starting point. Note that GHRH analogs are not interchangeable either: sermorelin clears in minutes while the DAC form persists for six to eight days.
The GH secretagogues carry the only hard food dependency here. An oral glucose load cut the growth-hormone response to a ghrelin agonist by roughly 60% in Broglio’s 2002 work, and a lipid load by roughly 42%. Worth a caveat the usual advice skips: the blunted ghrelin response still exceeded GHRH alone, so the two classes are not equally sensitive — free fatty acids nearly abolished the GHRH response. The conventional two-to-three-hour window is a practical heuristic rather than a trial-derived figure.
Acute vasoactive load is additive. NAD+, VIP, the GH secretagogues, PT-141, Melanotan II, B12 and the arginine in the 8X MIC blend each produce a flush independently, and their peaks land in the same short window. Co-administering several compounds one effect rather than producing several mild ones.
Only one compound carrying a GLP-1 arm. GLP-2 T, GLP-3 R, mazdutide and survodutide are dual and triple agonists rather than plain GLP-1 drugs, but each carries a GLP-1 arm and that arm is the source of the gastrointestinal burden. No trial has tested stacking two. Cagrilintide is the deliberate exception — amylin, a separate receptor. Even there the gain is additive rather than transformative: REDEFINE-1 produced roughly 22.7% weight loss against 16.1% for the GLP-1 alone.
Glucose moves in both directions across this catalog, and that is the part most often missed. The IGF compounds and the incretins push it down. The GH secretagogues push it up — in the tesamorelin trials 5% of subjects crossed HbA1c 6.5% versus 1% on placebo. Running both arms without monitoring fasting glucose and HbA1c is the most plausible route to quiet harm here.
Exogenous IGF on top of a secretagogue is double-dipping. Secretagogues already raise endogenous IGF-1. Adding LR3 or DES compounds both the hypoglycemia and the growth-promotion risk. The active-malignancy contraindication travels with the whole GH axis — tesamorelin is contraindicated in active malignancy and rhIGF-1 in active or suspected neoplasm, so it is not only an exogenous-IGF concern.
Rotate sites, always. Tesamorelin’s trials recorded injection-site reactions in 25% of subjects against 14% on placebo, and repeated same-site subcutaneous administration produces lipohypertrophy, which then alters the absorption kinetics of anything delivered there. Co-locating two compounds at one site compounds the local reaction and obscures which one caused it.
The repair family is the uncomplicated corner. BPC-157, TB-500, GHK-Cu, KPV and LL-37 carry no timing dependencies and no meaningful interactions with each other — combining them is what the Wolverine, GLOW and KLOW blends already are.
Copper has chemistry, and one incompatibility is worse than lost potency. EDTA and thiols such as glutathione and NAC simply outcompete GHK for the copper. Ascorbate is a different problem: it reduces Cu(II) to Cu(I), which GHK does not bind, and copper plus ascorbate forms a Fenton-type redox pair that actively generates reactive oxygen species. Separate syringes resolve all of it. Zinc is the weakest entry on that list.
Sedating and stimulating compounds sit at opposite ends of the day — and hexarelin is the trap. DSIP, Epitalon and Pinealon are evening compounds; NAD+, Semax and MOTS-c are daytime ones. The familiar advice to place a GHRP at bedtime for the nocturnal GH pulse specifically does not extend to hexarelin, which suppresses slow-wave sleep and raises overnight ACTH, cortisol and prolactin.

Hard flags

Items where the literature is unambiguous, or where the absence of literature is itself the finding.

ACE-031 — Phase 2 was halted in April 2011 for epistaxis, gum bleeding and telangiectasia, and the program was permanently discontinued in May 2013 after non-clinical toxicology work whose findings did not support further development. The bleeding paused it; the toxicology ended it.
FOXO4-DRI, PNC-27, SLU-PP-332 — no human safety, dosing or pharmacokinetic data exists for any of them. Every stacking verdict involving these is inference, not evidence.
Melanotan II — priapism is documented as a standalone effect; additive risk alongside a PDE5 inhibitor is mechanistically sound but not directly documented. More consequentially, there are published case reports of eruptive dysplastic nevi and melanoma in situ following use, which puts dermatologic surveillance in the same conversation.
PT-141 — the labelled contraindications are uncontrolled hypertension and known cardiovascular disease; it raises blood pressure and lowers heart rate for up to twelve hours. The oral-naltrexone item widely reported as a contraindication is in fact an interaction warning, and the hazard runs the other way: PT-141 significantly reduces naltrexone exposure, so the risk is treatment failure rather than harm from the combination. Focal hyperpigmentation of the face, gingiva or breasts occurred in about 1% over eight doses, and resolution after discontinuation was not confirmed in every case.
Incretins before surgery or sedation — the 2024 multisociety guidance replaced the earlier blanket hold with risk stratification: do not routinely withhold, use a 24-hour clear-liquid diet beforehand, and hold only where specific risk factors are present such as active dose escalation, high dose, ongoing GI symptoms or existing delayed gastric emptying. Separately, delayed gastric emptying alters oral drug absorption — tirzepatide’s labelling requires backup or non-oral contraception for four weeks after initiation and after each dose increase. The class also carries an MTC/MEN2 boxed warning, pancreatitis and dehydration risk, mandatory insulin and sulfonylurea dose reduction, and meaningful lean-mass loss.
The GH axis in anyone with active or suspected malignancy — not an exogenous-IGF-only concern, since secretagogues raise endogenous IGF-1. Growth hormone can also unmask central adrenal insufficiency and central hypothyroidism by inhibiting 11β-HSD1 and shifting T4 to T3, so anyone marginal on either axis can decompensate. Fluid retention, carpal-tunnel-type tingling and arthralgia are the most common real-world dose-limiting effects and are frequently omitted from stacking discussions entirely.
Immune-active compounds alongside autoimmune disease or immunosuppressants — Thymalin, Thymosin Alpha 1 and LL37 all push immune activity upward.
Hexarelin run continuously — chronic exposure attenuates the GH response over sixteen weeks, though short-term intranasal and oral administration did not show desensitisation. There is no head-to-head data establishing that it desensitises faster than other GHRPs; that is a community claim rather than a finding.

Same syringe, or separate?

The honest framing first. There is no published stability or compatibility data for combining any two of these compounds in a single syringe. Anything with a different reconstitution diluent or a different pH optimum should not be combined at all — a compound stable at pH 4.0–4.5 and one requiring 6.5–7.5 have no safe midpoint. What follows is convention, not evidence.
Conventionally combined: CJC-1295 without DAC alongside ipamorelin, which is literally what the blend is; BPC-157 alongside TB-500; and the GLOW and KLOW components, which already ship pre-combined.
Kept separate: anything containing copper alongside glutathione, NAC or ascorbate; anything alongside insulin, which is formulated at roughly pH 4.0 with its own excipients; and any large peptide at high concentration alongside a much smaller one, where aggregation can trap the smaller molecule.
Bacteriostatic water reconstitutes essentially everything in the catalog. Its benzyl alcohol preservative carries a total-volume limit and a beyond-use date, and is incompatible with a small number of sensitive biologics that specify preservative-free sterile water instead.
Blood pressure runs in both directions here. PT-141 raises it for up to twelve hours while VIP, NAD+ and Melanotan II push the other way. Same-day combination of opposing hemodynamic agents is a real consideration rather than a theoretical one.

Common questions

Can BPC-157 and TB-500 be combined?

Yes — they are complementary rather than redundant. BPC-157 drives local angiogenesis and growth-factor signalling while TB-500 promotes cell migration and broader tissue remodelling. The two are already sold pre-combined as the Wolverine blend, and neither carries a timing dependency.

Why does CJC-1295 / Ipamorelin cause flushing?

It is a direct receptor-level vascular effect of the GHRH analog, not the growth-hormone pulse itself. Subcutaneous GH does not peak until 20 to 60 minutes, so a flush appearing at 5 to 15 minutes cannot be caused by it. Sermorelin’s own labelling places facial flushing under 1%, largely at intravenous diagnostic doses.

Can two GH secretagogues be used together?

One GHRH analog plus one ghrelin-receptor agonist is genuinely superadditive and was demonstrated in normal men by Bowers in 1990. Two GHRH analogs, or two ghrelin-receptor agonists, are redundant at the same receptor and add side effects without adding growth hormone.

Can two GLP-1 compounds be combined?

No trial has tested it. The reasoning against it is receptor saturation plus the well-documented dose-dependence of gastrointestinal adverse events, which means additive nausea, vomiting and gastroparesis risk without additional efficacy. Cagrilintide is the exception because it is an amylin analog acting on a separate receptor.

Which peptides should not share a syringe?

There is no published stability data for combining any two of these in one syringe. The clearest chemical incompatibility is copper: GHK-Cu should not share a vial with glutathione, NAC, EDTA or ascorbate, which either outcompete GHK for the copper or, in ascorbate’s case, form a redox pair that generates reactive oxygen species.

How these verdicts were built

Each compound is scored on four axes — receptor family, direction of glucose effect, acute vasoactive load, and timing dependency — and every pair is evaluated against a fixed rule set rather than assessed individually. That makes the reasoning inspectable: a “redundant” verdict always traces to a shared receptor, and a “space apart” verdict always traces to combined load or opposing windows. Half-lives are literature values. Several verdicts rest on receptor-level reasoning or preclinical data rather than human trials, and are labelled where that is the case.

Compound profiles, mechanisms and citations live in the Peptides A–Z encyclopedia. Background on how these molecules work is in What Are Peptides.

For research and educational use only. This page describes how compounds behave in published research and does not constitute a protocol, dosing guidance, medical advice or a recommendation of any kind. All compounds discussed are intended solely for laboratory and research use and are not for human or veterinary consumption. See the full disclaimer.